All lobbying filings

THE NICKLES GROUP, LLC

Lobbying for NOVO NORDISK, INC. · Pharmaceutical company.

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $80,000.00 income · posted Jan 20, 2026

Official filing document

Bills named in this filing 4

HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
HR 591
Defending American Jobs and Investment Act
HR 2423
Unfair Tax Prevention Act

Lobbying activity 4

Health Issues

Issues related to compounding and counterfeit drugs.

Medicare/Medicaid

Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to coverage of anti-obesity medications. Issues related to pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing.

Taxation/Internal Revenue Code

Monitor issues related to the implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes and foreign-based multinationals. Monitor OECD negotiations on the Pillar II global minimum tax. H.R. 591, Defending American Jobs and Investment Act, and H.R. 2423, Unfair Tax Prevention Act, as they relate to multinational corporations.

Trade (domestic/foreign)

Issues related to tariffs. Issues related to importation of counterfeit drugs.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.